Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 668

1.

Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns.

Soresi M, Terranova A, Licata A, Serruto A, Montalto G, Brancatelli G, Giannitrapani L.

Biomed Res Int. 2017;2017:4932759. doi: 10.1155/2017/4932759. Epub 2017 May 30.

2.

Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.

Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M.

World J Gastroenterol. 2017 May 28;23(20):3690-3701. doi: 10.3748/wjg.v23.i20.3690.

3.

Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay.

Nowicki TK, Markiet K, Szurowska E.

Curr Med Imaging Rev. 2017 May;13(2):140-153. doi: 10.2174/1573405612666160720123748.

4.

Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma.

Suh SW, Choi YS.

Yonsei Med J. 2017 Jul;58(4):737-742. doi: 10.3349/ymj.2017.58.4.737.

5.

Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?

Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH.

Hepatobiliary Surg Nutr. 2017 Apr;6(2):105-116. doi: 10.21037/hbsn.2017.01.16. Review.

6.

Evaluation of response after SBRT for liver tumors.

Tétreau R, Llacer C, Riou O, Deshayes E.

Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):170-175. doi: 10.1016/j.rpor.2015.12.004. Epub 2015 Dec 30.

PMID:
28490989
7.

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.

Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M.

World J Gastroenterol. 2017 Apr 14;23(14):2545-2555. doi: 10.3748/wjg.v23.i14.2545.

8.

Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector.

Liu Q, Yang Y, Tan X, Tao Z, Adah D, Yu S, Lu J, Zhao S, Qin L, Qin L, Chen X.

Oncotarget. 2017 Apr 11;8(15):24785-24796. doi: 10.18632/oncotarget.15806.

9.

Outcomes of microwave ablation for hepatocellular carcinoma adjacent to large vessels: a propensity score analysis.

Dou JP, Yu J, Yang XH, Cheng ZG, Han ZY, Liu FY, Yu XL, Liang P.

Oncotarget. 2017 Apr 25;8(17):28758-28768. doi: 10.18632/oncotarget.15672.

10.

Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients.

Shaker MK, Abdel Fattah HI, Sabbour GS, Montasser IF, Abdelhakam SM, El Hadidy E, Yousry R, El Dorry AK.

World J Hepatol. 2017 Mar 28;9(9):469-476. doi: 10.4254/wjh.v9.i9.469.

11.

The importance of a multidisciplinary approach to hepatocellular carcinoma.

Siddique O, Yoo ER, Perumpail RB, Perumpail BJ, Liu A, Cholankeril G, Ahmed A.

J Multidiscip Healthc. 2017 Mar 20;10:95-100. doi: 10.2147/JMDH.S128629. eCollection 2017. Review.

12.

Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence.

Liao Y, Zheng Y, He W, Li Q, Shen J, Hong J, Zou R, Qiu J, Li B, Yuan Y.

Oncol Lett. 2017 Feb;13(2):984-992. doi: 10.3892/ol.2016.5525. Epub 2016 Dec 20.

13.
14.

Left jackknife position: a novel position for laparoscopic hepatectomy.

Chen JC, Zhang RX, Chen MS, Xu L, Chen JB, Yang KL, Zhang YJ, Zhou ZG.

Chin J Cancer. 2017 Mar 20;36(1):31. doi: 10.1186/s40880-017-0190-y.

15.

Review.

Kallwitz ER.

Gastroenterol Hepatol (N Y). 2006 Aug;2(8):603-604. Review. No abstract available.

16.

Medical Care of the Patient With Compensated Cirrhosis.

Herrera JL, Rodríguez R.

Gastroenterol Hepatol (N Y). 2006 Feb;2(2):124-133.

17.

Impact of clinically significant portal hypertension on surgical outcomes for hepatocellular carcinoma in patients with compensated liver cirrhosis: a propensity score matching analysis.

Jang CW, Kwon HJ, Kong H, Ha H, Han YS, Chun JM, Kim SG, Hwang YJ.

Ann Hepatobiliary Pancreat Surg. 2016 Nov;20(4):159-166. doi: 10.14701/ahbps.2016.20.4.159. Epub 2016 Nov 30.

18.

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE.

Huang WK, Yang SF, You LN, Liu M, Liu DY, Gu P, Fan XW.

Contemp Oncol (Pozn). 2016;20(6):468-474. doi: 10.5114/wo.2016.65607. Epub 2017 Jan 12.

19.

Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment.

Zhang GL, Chen YM, Zhang T, Cai QX, Zhang XH, Zhao ZX, Lin CS, Gao ZL.

Biomed Res Int. 2017;2017:8061091. doi: 10.1155/2017/8061091. Epub 2017 Jan 23.

20.

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.

Subbiah V, Chuang HH, Gambhire D, Kairemo K.

Diagnostics (Basel). 2017 Feb 15;7(1). pii: E10. doi: 10.3390/diagnostics7010010.

Supplemental Content

Support Center